ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
20 hedge funds and large institutions have $464K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
13% less funds holding
Funds holding: 23 → 20 (-3)
23% less capital invested
Capital invested by funds: $601K → $464K (-$137K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.4K |
| 2 |
Renaissance Technologies
New York
|
+$14.6K |
| 3 |
Invesco
Atlanta,
Georgia
|
+$3.21K |
| 4 |
RCAG
Rehmann Capital Advisory Group
Lansing,
Michigan
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$94K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$67.2K |
| 3 |
VF
Virtu Financial
New York
|
-$27.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$10K |
IMUC Hedge Fund Activity: Q2 2018 in Review
20 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q2 2018, worth a combined $464K — down 23% from $601K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMUC and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Vanguard Group, adding an estimated $53.4K. The largest seller was Millennium Management, exiting entirely with an estimated $94K sold.
- 20 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q2 2018, down from 23 in Q1 2018.
- Funds reported $464K of ImmunoCellular Therapeutics, Ltd. stock for Q2 2018, down 23% quarter-over-quarter.
- 2 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q2 2018 and 5 closed out, a net change of -3 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q2 2018 was Vanguard Group, an estimated $53.4K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q2 2018 was Millennium Management, an estimated $94K sold.
Based on aggregated 13F filings for Q2 2018.